World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
74
Citations
28669
World Ranking
19290
National Ranking
9609

Overview

Arturo Molina is affiliated with Sutro Biopharma in the United States and has contributed extensively to the field of medicine, with a focus on genetics, hematology, molecular biology, oncology, and pathology and forensic medicine.

Their research work spans several areas including myeloproliferative neoplasms diagnosis and treatment, hemoglobinopathies and related disorders, acute myeloid leukemia research, chronic myeloid leukemia treatments, acute lymphoblastic leukemia research, lymphoma diagnosis and treatment, and macrophage migration inhibitory factor.

Frequent coauthors collaborating with Molina include Andrew Kuykendall, Sarita Khanna, Suneel Gupta, Naveen Pemmaraju, and Kristen Pettit, with collaboration counts ranging from 10 to 12 publications each.

Publications by Arturo Molina have appeared in various journals, with multiple papers featured in prominent venues such as Blood, the Journal of Clinical Oncology, Clinical Lymphoma Myeloma & Leukemia, Blood Advances, and Cancer Research.

Selected recent papers include:

  • "Rusfertide, a Hepcidin Mimetic, for Control of Erythrocytosis in Polycythemia Vera", 2024, New England Journal of Medicine
  • "Targeting FOLR1 in high-risk CBF2AT3-GLIS2 pediatric AML with STRO-002 FOLR1-antibody-drug conjugate", 2022, Blood Advances
  • "Preclinical studies targeting CD74 with STRO-001 antibody-drug conjugate in acute leukemia", 2023, Blood Advances
  • "Targeting CD74 in B-cell non-Hodgkin lymphoma with the antibody-drug conjugate STRO-001", 2023, Oncotarget
  • "Phase 1 dose-escalation study of STRO-002, an antifolate receptor alpha (FRα) antibody drug conjugate (ADC), in patients with advanced, progressive platinum-resistant/refractory epithelial ovarian cancer (EOC).", 2021, Journal of Clinical Oncology

Best Publications

  • Abiraterone and Increased Survival in Metastatic Prostate Cancer

    Johann S. de Bono;Christopher J. Logothetis;Arturo Molina;Karim Fizazi

  • Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy

    Charles J. Ryan;Matthew R. Smith;Johann S. De Bono;Arturo Molina

  • Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study

    Karim Fizazi;Howard I. Scher;Arturo Molina;Christopher J. Logothetis

  • Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study

    Charles J. Ryan;Matthew R. Smith;Karim Fizazi;Fred Saad

  • Pivotal Phase III Trial of Two Dose Levels of Denileukin Diftitox for the Treatment of Cutaneous T-Cell Lymphoma

    Elise Olsen;Madeleine Duvic;Arthur Frankel;Youn Kim

  • Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer

    Gerhardt Attard;Alison H.M. Reid;Roger A'Hern;Christopher Parker

  • Characterization of ERG, AR and PTEN Gene Status in Circulating Tumor Cells from Patients with Castration-Resistant Prostate Cancer

    Gerhardt Attard;Joost F. Swennenhuis;David Olmos;Alison H.M. Reid

  • Phase II Multicenter Study of Abiraterone Acetate Plus Prednisone Therapy in Patients With Docetaxel-Treated Castration-Resistant Prostate Cancer

    Daniel C. Danila;Michael J. Morris;Johann S. De Bono;Charles J. Ryan

  • Significant and Sustained Antitumor Activity in Post-Docetaxel, Castration-Resistant Prostate Cancer With the CYP17 Inhibitor Abiraterone Acetate

    Alison H.M. Reid;Gerhardt Attard;Daniel C. Danila;Nikhil Babu Oommen

  • Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma.

    Koen Van Besien;Fausto R. Loberiza;Ruta Bajorunaite;James O. Armitage

  • Circulating Tumor Cell Biomarker Panel As an Individual-Level Surrogate for Survival in Metastatic Castration-Resistant Prostate Cancer

    Howard I Scher;Glenn Heller;Arturo Molina;Gerhardt Attard

  • Phase I Clinical Trial of the CYP17 Inhibitor Abiraterone Acetate Demonstrating Clinical Activity in Patients With Castration-Resistant Prostate Cancer Who Received Prior Ketoconazole Therapy

    Charles J. Ryan;Matthew R. Smith;Lawrence Fong;Jonathan E. Rosenberg

  • Solid Cancers After Bone Marrow Transplantation

    Smita Bhatia;Andrew D. Louie;Ravi Bhatia;Margaret R. O’Donnell

  • Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors.

    Amrita Krishnan;Smita Bhatia;Marilyn L. Slovak;Daniel A. Arber

  • Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302)

    Dana E. Rathkopf;Matthew R. Smith;Johann S. De Bono;Christopher J. Logothetis

  • Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: Long-term follow-up of a phase 1/2 study

    Leo I. Gordon;Arturo Molina;Thomas Witzig;Christos Emmanouilides

  • Rituximab: expanding role in therapy for lymphomas and autoimmune diseases.

    William Rastetter;Arturo Molina;Christine A White

  • Phase II Study of Abiraterone Acetate in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Displaying Bone Flare Discordant With Serologic Response

    Charles J. Ryan;Shreya Shah;Eleni Efstathiou;Matthew R. Smith

  • Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial

    Christopher J Logothetis;Ethan Basch;Arturo Molina;Karim Fizazi

  • Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: A Comparison With Prostate-Specific Antigen Across Five Randomized Phase III Clinical Trials

    Glenn Heller;Robert McCormack;Thian Kheoh;Arturo Molina

Frequent Co-Authors

Howard I. Scher
Howard I. Scher Memorial Sloan Kettering Cancer Center
Johann S. de Bono
Johann S. de Bono Institute of Cancer Research
Karim Fizazi
Karim Fizazi University of Paris-Saclay
Stephen J. Forman
Stephen J. Forman City Of Hope National Medical Center
Eric J. Small
Eric J. Small University of California, San Francisco
Matthew R. Smith
Matthew R. Smith Harvard University
Fred Saad
Fred Saad University of Montreal
Christopher J. Logothetis
Christopher J. Logothetis The University of Texas MD Anderson Cancer Center
Peter F.A. Mulders
Peter F.A. Mulders Radboud University
Leo I. Gordon
Leo I. Gordon Northwestern University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students interested in medical studies, there are several online degree options and accelerated career pathways worth exploring. Online healthcare programs can offer greater flexibility and often allow for a faster route to professional practice.

Many nursing professionals are looking to advance their credentials efficiently. Accelerated DNP programs online are designed for experienced nurses seeking top-level roles, offering rigorous coursework that can be completed in less time than traditional programs.

If dissertation requirements are a concern, there are online DNP programs without dissertation that allow candidates to focus on clinical practice and leadership training instead of lengthy research projects.

Those aiming to enter the workforce more quickly may benefit from fast track LPN programs online, streamlining the path to becoming a Licensed Practical Nurse with curriculum designed for speed and accessibility.

For advanced practitioners, the fastest post master's PMHNP programs offer a direct route to becoming a Psychiatric Mental Health Nurse Practitioner, addressing a growing demand in mental health care.

Best Scientists Citing Arturo Molina

Trending Scientists

Recently Published Articles